Use of salivary caffeine tests to assess the inducer effect of a drug on hepatic metabolism

Annals of Pharmacotherapy

Volumn 30, Issue 7-8, 1996, Pages 736-739

  Soto, Javier ^a   Sacristan, Jose A ^a   Alsar, Maria J ^b  

^a Hospital Santa Cruz   (Spain)

^b HOSPITAL DE LAREDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLEARANCE; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIVER METABOLISM; LONGITUDINAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALIVA ANALYSIS; SALIVA LEVEL;

EID: 0030035251     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000705     Document Type: Article

References (28)

1. Park BK, Breckenridge AM. Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 1981;6:1-24.
2. Poulsen HE, Loft S. Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol 1988;6:374-82.
3. Park BK. Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol 1982;14:631-51.
4. Renner E, Wietholtz H, Huguenin P, Arnaud MJ, Preising R. Caffeine: a model compound for measuring liver function. Hepatology 1984;4:38-46.
5. Vial T, Descotes J, Evreux JCL. Le test à la caféine. Therapie 1989;44: 245-51.
6. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-14.
7. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garatti S. Caffeine disposition after oral doses. Clin Pharmacol Ther 1982;32:98-106.
8. Blanchard J, Sawers SJA. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 1983;24:93-8.
9. Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol 1981;21:45-52.
10. Zylber-Katz E, Granit LL, Levy M. Relationship between caffeine concentrations in plasma and saliva. Clin Pharmacol Ther 1984;36:133-7.
11. Wahlländer A, Mohr S, Paumgartner G. Assessment of hepatic function: comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatol 1990;10:129-37.
12. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987;42:157-65.
13. Blanchard J, Sawers SJA, Jonkman JHG, Tang-Liu DDS. Comparison of the urinary metabolite profile of caffeine in young and elderly males. Br J Clin Pharmacol 1985;19:225-32.
14. Scott NR, Chakraborty J, Marks V. Urinary metabolites of caffeine in pregnant women. Br J Clin Pharmacol 1986;22:475-8.
15. Ullrich D, Compangnone D, Münch B, Brandes A, Hille H, Bircher J. Urinary caffeine metabolites in man: age-dependent changes and pattern in various clinical situations. Eur J Clin Pharmacol 1992;43:167-72.
16. Venkatesan K. Pharmacokinetic drug interactions with rifampin. Clin Pharmacokinet 1992;22:47-65.
17. Ohnhaus EE, Park BK. Measurement of urinary 6β-hydroxy-cortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampin. Eur J Clin Pharmacol 1979;15:139-45.
18. Ohnhaus EE, Gerber-Taras E, Park BK. Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man. Eur J Clin Pharmacol 1983;24:247-50.
19. O'Reilly RA. Interaction of sodium warfarin and rifampin. Studies in man. Ann Intern Med 1974;81:337-40.
20. Branch RA, Herman RJ. Enzyme induction and beta-adrenergic receptor blocking drugs. Br J Clin Pharmacol 1984;17(suppl):77S-84S.
21. Zhon HH, Anthony LB, Wood AJ, Wilkinson GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampin. Br J Clin Pharmacol 1990;30:471-5.
22. Blanchard J, Mohammadi JD, Conrad KA. Improved liquid-chromatographic determination of caffeine in plasma. Clin Chem 1980;26:1351-4.
23. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982.
24. Metzler CM, Elfring GK, McEwen AJ. A package of computer programs for pharmacokinetic modeling. Biometrics 1974;30:562-3.
25. Beaune P. Human cytochromes P450. Applications in pharmacology. Therapie 1993;48:521-6.
26. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
27. Bachmann K, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993;23:307-15.
28. Watkins PB. Drug metabolism by cytochromes P-450 in the liver and small bowel. Gastroenterol Clin North Am 1992;21:511-26.